Skip to main content

Novel Rx

      Anakinra in Pediatric, Adult Still's Disease: Dr. Bella Mehta

      Dr. Bella Mehta reviews abstract #1633 at the 2020 ACR annual meeting. 

       

      RT @MeralElRamahiMD: Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticas

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 10 months ago
      Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE
      RT @drpnash: Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Ph

      Peter Nash drpnash

      4 years 10 months ago
      Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials https://t.co/70oOHXihFb #SLE #zoster x 4-5 times increase in zoster
      RT @drdavidliew: How do we dose maintenance rituximab in AAV to optimise B cell depletion but minimise hypogammaglob?

      D

      David Liew drdavidliew

      4 years 10 months ago
      How do we dose maintenance rituximab in AAV to optimise B cell depletion but minimise hypogammaglob? Drug levels may be the answer. In this cohort (n=61) trough >550ng/mL: all B cell depleted >1000ng/mL: all got hypogammaglob very interesting concept! #ACR20 ABST1438 @RheumNow https://t.co/0pcl0BW2Tv
      RT @RHEUMarampa: Data from BIOBADASER 3 showed that there was a ⬇ in the incidence of S. pneumonia-related infxns in R

      sheila RHEUMarampa

      4 years 10 months ago
      Data from BIOBADASER 3 showed that there was a ⬇ in the incidence of S. pneumonia-related infxns in RA pts on b/tsDMARD after receiving the stepwise combined vax scheme (conj+PS) @RheumNow #ACR20 abs1465 #VaccinesWork https://t.co/KlestmKfaO
      Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy

      Dr. John Cush RheumNow

      4 years 10 months ago

      Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9

      Potpourri of Pathotypes of Predictors with RA Faculty

      Dr. Jonathan Kay again leads an international panel of rheumatologists to elicit their opinions on key abstracts at ACR 2020. Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.

      1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure.

      Dr. John Cush RheumNow

      4 years 10 months ago

      1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap

      Study of 351 SLE patients from Leiden shows that SLE with Neuropsychatric disease do not have a higher mortality than lu

      Dr. John Cush RheumNow

      4 years 10 months ago
      Study of 351 SLE patients from Leiden shows that SLE with Neuropsychatric disease do not have a higher mortality than lupus without CNS disease; but do have higher mortality than gen. population #ACR20 Abstr#1264 https://t.co/CmBjfUj1Ur https://t.co/WYZQDaI4yt
      RT @KDAO2011: ACR/AF JIA guidelines presented @ACR20:
      👉Initiate DMARD early over NSAID monotherapy
      👉Use SQ MTX&gt

      k dao KDAO2011

      4 years 10 months ago
      ACR/AF JIA guidelines presented @ACR20: 👉Initiate DMARD early over NSAID monotherapy 👉Use SQ MTX> oral MTX > SSZ/LEF 👉add biologic preferred over triple DMARD 👉DON'T use chronic low dose steroids 👉combo biologic+DMARD > biologic monoRx https://t.co/lwoFSTuV91 @rheumnow https://t.co/wzh2LCS0dN
      Pegloticase in Severe Refractory Gout: Dr. Olga Petryna

      Dr. Petryna reviews several pegloticase-related abstracts presented at the ACR 2020 annual meeting, including abstracts #0683 and #0677

      RT @ejdein1: Trivia from John Stone's pearls talk: Which is the biggest risk factor for disease flare in GCA? (All are s

      Eric Dein ejdein1

      4 years 10 months ago
      Trivia from John Stone's pearls talk: Which is the biggest risk factor for disease flare in GCA? (All are statistically signif RFs). #ACR20 @RheumNow
      RT @ejdein1: John Stone: "The HISTORY is the Rheumatologist's scalpel." TA bx is not gold standard in diagnosis, as not

      Eric Dein ejdein1

      4 years 10 months ago
      John Stone: "The HISTORY is the Rheumatologist's scalpel." TA bx is not gold standard in diagnosis, as not fully sensitive. @RheumNow #ACR20.
      RT @drdavidliew: Abatacept in IgG4-RD. Plausible, but does it work?

      Pilot n=10 @MGHrheumatology
      ABA +&lt;4w PNL

      Some h

      David Liew drdavidliew

      4 years 10 months ago
      Abatacept in IgG4-RD. Plausible, but does it work? Pilot n=10 @MGHrheumatology ABA +<4w PNL Some hit, some miss - but mechanistic correlates of response: Tfh2, unswitched memory B cells. Exploring new options (w real benefit) very welcome in IgG4-RD! #ACR20 ABST1480 @RheumNow https://t.co/0saS941Lga
      RT @KDAO2011: #ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE:
      1. HCQ is the foundation of Rx
      2

      k dao KDAO2011

      4 years 10 months ago
      #ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE: 1. HCQ is the foundation of Rx 2. keep pred <7.5mg/day 3. belimumab works better when given early in disease (<2 yrs) 4. combination Rx may be needed @rheumnow https://t.co/6zh1xkLXgN
      ×